FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge

Feline immunodeficiency virus: In vivo protection remains elusive A vaccine candidate for feline immunodeficiency virus elicits strong immunological reaction in vitro, but no protection to live cats. The feline analog to human immunodeficiency virus, FIV shares a similar infection paradigm and has o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Craig Miller, Mauren Emanuelli, Elizabeth Fink, Esther Musselman, Ryan Mackie, Ryan Troyer, John Elder, Sue VandeWoude
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Acceso en línea:https://doaj.org/article/205cd096895a417caabb9e554d669d75
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Feline immunodeficiency virus: In vivo protection remains elusive A vaccine candidate for feline immunodeficiency virus elicits strong immunological reaction in vitro, but no protection to live cats. The feline analog to human immunodeficiency virus, FIV shares a similar infection paradigm and has only one partially effective vaccine. A US team, led by Colorado State University’s Susan VandeWoude, immunized cats using a complex of an FIV surface protein and a feline cell-surface protein known to facilitate FIV’s entry into immune cells. Tissue culture assays yielded promising results; however, this did not translate to live-animal protection. The researchers highlighted multiple factors that could explain the lack of success, including circulatory pro-infection factors, and immune responses generated against vaccine by-products rather than intended targets. While the vaccine candidate failed, the research provides invaluable guidance for future efforts into FIV vaccination with implications for HIV vaccine trials.